Abbott announced that its FreeStyle Libre 3 sensor can be now used with the mylife Loop solution from Swiss infusion systems specialist Ypsomed and digital health firm CamDiab.

The integration will create a smart, automated solution that delivers insulin based on real-time glucose data.

It combines CamDiab’s CamAPS FX mobile app and Ypsomed’s mylife YpsoPump with accurate, real-time data from Abbott’s FreeStyle Libre 3 sensor.

The company is offering the automated insulin delivery system (AID) solution currently in Germany, with plans to expand to additional European countries starting in 2023.

In addition to partnership with Ypsomed and CamDiab, it is also working with other insulin delivery systems interoperability with its FreeStyle Libre platform, said Abbott.

Abbott diabetes care business senior vice president Jared Watkin said: “Our FreeStyle Libre portfolio is already helping to improve the lives of 4.5 million people around the world who are living with diabetes.

“We’re partnering with diabetes and digital health technology leaders like Ypsomed and CamDiab to deliver new innovative solutions that make diabetes care as easy as possible, so people can spend less time worrying about their diabetes and more time living.”

According to JDRF’s Type 1 Diabetes Index, an average person living with Type 1 diabetes in Germany loses 18.5 healthy years, if their diabetes is not properly managed.

Effective glucose monitoring and automated insulin delivery devices could help people with diabetes restore around five healthy years.

Abbott said that its integrated solution will continuously monitor a person’s glucose levels, and automatically adjusts and delivers the right amount of insulin at the right time.

Its AID solution will eliminate the issues related to insulin dosing and helps people with diabetes reach better treatment targets, said the company.

HealthPartners Institute international diabetes centre executive director Rich Bergenstal said: “As healthcare providers, one of the biggest challenges of insulin therapy is when glucose levels get dangerously low.

“Technological innovations, like automated insulin delivery systems, can ease some of that uncertainty by continuously monitoring a person’s glucose levels and delivering the right insulin dosage, which can ultimately improve time in range. And better glucose control reduces diabetes complications.”